COVID-19–related data reported at the 63rd ASH Annual Meeting and Exposition included the specific experiences of a large group of patients with ch......READ MORE
As seen at the 63rd ASH Annual Meeting and Exposition, treatment-free remission (TFR) is an important goal in chronic myeloid leukemia (CML). Facto......READ MORE
Dose optimization may improve persistence with tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia (CP-CML). New data......READ MORE
As reflected in data presented at the 63rd ASH Annual Meeting and Exposition, efforts are underway to refine current approaches to the management o......READ MORE
At the 63rd ASH Annual Meeting and Exposition, patterns of care in chronic myeloid leukemia (CML) were explored using real-world analyses. The data......READ MORE
At the 63rd ASH Annual Meeting and Exposition, several presentations on chronic-phase chronic myeloid leukemia (CP-CML) provided data that may add ......READ MORE